Convalescent Plasma Use in the United States was inversely correlated with COVID-19 Mortality: Did Plasma Hesitancy cost lives?

BACKGROUND. The US Food and Drug Administration authorized Convalescent Plasma (CCP) therapy for hospitalized COVID-19 patients via the Expanded Access Program (EAP) and the Emergency Use Authorization (EUA), leading to use in about 500,000 patients during the first year of the pandemic for the US....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:medRxiv
Hauptverfasser: Casadevall, Arturo, Dragotakes, Quigly, Johnson, Patrick W., Senefeld, Jonathon W., Klassen, Steven A., Wright, R. Scott, Joyner, Michael J, Paneth, Nigel, Carter, Rickey E.
Format: Artigo
Sprache:Inglês
Veröffentlicht: Cold Spring Harbor Laboratory 2021
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8043483/
https://ncbi.nlm.nih.gov/pubmed/33851186
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2021.04.07.21255089
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge